Giredestrant's lidERA win: oral SERDs reach the adjuvant setting

On June 2, 2026 the FDA accepted and granted priority review to Roche's new drug application for giredestrant in early-stage ER+, HER2-negative breast cancer. It is the first oral selective estrogen receptor degrader (SERD) to post a positive phase 3 readout in the curative setting, and it lands after a high-profile metastatic flop for the same molecule. The split result is a good lesson in why where you test an endocrine agent matters as much as what the agent does.

What a SERD actually does

Estrogen receptor alpha (ERα, gene ESR1) is the dependency that defines roughly 70% of breast cancers. The decades-old standard is to starve the receptor of ligand with an aromatase inhibitor, or to block it with the SERM tamoxifen. SERDs go further: they bind the ligand-binding domain, destabilize the receptor, and route it for proteasomal degradation, so the cell loses the protein entirely rather than just having it occupied. Fulvestrant proved the mechanism works but it is an intramuscular injection with poor exposure. The whole oral SERD race has been about getting that degradation pharmacology into a once-daily pill.

The clinical urgency is a single recurring mutation. ESR1 mutations in the ligand-binding domain, dominated by Y537S and D538G, are acquired under aromatase-inhibitor pressure and lock the receptor into a constitutively active conformation that no longer needs estrogen. They are found in up to 40% of endocrine- pretreated metastatic tumors, and they are the reason elacestrant (the first approved oral SERD) carries an ESR1-mutation-restricted label. A SERD that degrades the mutant is the point of the class.

lidERA: the adjuvant win

lidERA Breast Cancer (NCT04961996) randomized 4,170 patients with resected, medium- or high-risk stage I to III ER+, HER2-negative disease to 30 mg giredestrant daily or physician's choice of standard endocrine therapy for at least five years. Adjuvant giredestrant cut the risk of invasive recurrence or death by 30% (HR 0.70; 95% CI, 0.57 to 0.87; P = .0014). The benefit held across menopausal status, with a hazard ratio of 0.65 in the 1,687 premenopausal patients and 0.74 in the 2,456 postmenopausal patients. The PDUFA target action date is November 30, 2026.

• Giredestrant (Roche) — oral SERD; first in the class to improve invasive disease-free survival as adjuvant therapy in early ER+ disease. NDA under FDA priority review as of June 2026.
• Elacestrant (Orserdu, Stemline/Menarini) — the first FDA-approved oral SERD (2023), restricted to ESR1-mutant metastatic disease after progression on endocrine therapy.
• Camizestrant and imlunestrant — later oral SERDs reading out in the metastatic and early settings; the class is converging on ESR1-mutant selectivity plus combinability with CDK4/6 inhibitors.

The persevERA caution

The same drug missed its primary endpoint in persevERA, the phase 3 first-line metastatic study pairing giredestrant with palbociclib against the standard aromatase-inhibitor combination. Progression- free survival did not reach statistical significance. The contrast with lidERA is instructive: in the adjuvant setting you are suppressing micrometastatic, largely treatment-naive disease where clean ER degradation has room to help, while in heavily co-treated first-line metastatic disease the bar set by an established CDK4/6 combination is high and the tumors are more heterogeneous. The molecule did not change between trials. The disease context did.

Try the docking yourself

The interesting structural biology for this class is the Y537S mutant, where the substituted serine hydrogen-bonds to D351 and stabilizes the agonist conformation of helix 12 even with no ligand bound. That is what an oral SERD has to overcome. Open Studio and pick ESR1 from the target catalog with the Y537S mutation chip, then dock a SERD scaffold against both the wild-type and mutant ligand-binding domain. The molecular docking pose for a basic-side- chain SERD should show the amine reaching toward the helix-12 path that drives degradation, and the ΔΔ between mutant and wild-type is the structure-level readout of why ESR1-mutant selectivity is hard.

Liganx is molecular docking online and free in the browser, set up for exactly this kind of mutant-versus-wildtype comparison. If you want to run molecular docking on ESR1 Y537S without a local install, it is the fastest path.

Primary sources

• Roche. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer. Media release, 2 June 2026. roche.com/media/releases/med-cor-2026-06-02
• Jhaveri K, et al. lidERA Breast Cancer: phase III adjuvant study of giredestrant vs physician's choice of endocrine therapy in ER+, HER2- early breast cancer. ASCO Annual Meeting 2026 (abstr). asco.org/abstracts-presentations/225743
• Bidard FC, et al. Elacestrant for ER-positive, HER2-negative advanced breast cancer with ESR1 mutations (EMERALD). J Clin Oncol 40, 3246-3256 (2022). doi:10.1200/JCO.22.00338